Clinical trials: Differentiation
Neuroendocrine Tumors, Well-Differentiated Neuroendocrine Carcinoma
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
This is the first study to be done in a newly described class of neuroendocrine tumors known as well-differentiated grade 3 neuroendocrine tumors (WD G3 NET).
- Conditions
- Neuroendocrine Tumors, Well-Differentiated Neuroendocrine Carcinoma, High Grade Neuroendocrine Carcinoma, Any Site
- Trial name
- NCT05746208
- Testing
- Lenvatinib, Pembrolizumab, Hyperpolarized 13C-Pyruvate
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of California, San Francisco
Thyroid Cancer
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
Study rationale High risk patients with differentiated thyroid cancer (DTC) require therapy with 131 I under thyroid stimulating hormone (TSH) stimulation.
- Trial name
- NCT03841617
- Testing
- Thyrogen, I-131, I-124
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Osteoporosis
Thiazolidinediones (TZD) Bone Loss and the Effects on Bone Marrow Differentiation and Osteoblast Formation
Thiazolidinediones (TZDs) are a commonly used antidiabetic drugs currently used by over a million patients in the United States. Recent studies have shown that treatment with TZD may increase the risk of bone fractures.
- Trial name
- TZDBONE (NCT00663143)
- Testing
- Stromal Cells Sample
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Emory University
Advanced Solid Tumor, Metastatic Solid Tumor
Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors
This is an open-label, multicenter, phase 2 study of lurbinectedin monotherapy in participants with advanced (metastatic and/or unresectable) solid tumors.
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Urothelial Cancer, Poorly Differentiated Neuroendocrine Carcinomas
- Trial name
- JAZZ EMERGE201 (NCT05126433)
- Testing
- Lurbinectedin
- Where
- 17 sites in United States
- Volunteers
- 47 people
- Sponsor
- Jazz Pharmaceuticals
Atrial Fibrillation, Ischemic Heart Disease
Dynamic Changes in SDF-1α Levels in Acute and Stabilized Heart Disease
The aims of the present study are to measure dynamic changes over time in the plasma level of SDF-1α in patients with confirmed diagnoses of AMI, AF and CHF and in so doing: 1.
- Conditions
- Atrial Fibrillation, Ischemic Heart Disease, Congestive Heart Failure
- Trial name
- DYNASDY (NCT02702752)
- Testing
- DYNASDY
- Where
- Denmark
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Hvidovre
Leukemia, Myelodysplastic Syndromes
Early Discharge and Outpatient Care After Chemotherapy in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
RATIONALE: Gathering information about patients with myelodysplastic syndrome or acute myeloid leukemia who are discharged after finishing chemotherapy, or who stay in the hospital until blood counts return to normal, may help…
- Trial name
- NCT00844441
- Testing
- medical chart review, questionnaire administration, quality-of-life assessment
- Where
- 3 sites in United States, Switzerland
- Volunteers
- 96 people
- Sponsor
- Fred Hutchinson Cancer Center
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
This phase I trial is studying the side effects and best dose of tipifarnib and etoposide in treating older patients with newly diagnosed acute myeloid leukemia.
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b)
- Trial name
- NCT00112853
- Testing
- tipifarnib, etoposide
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Cancer Institute (NCI)
Differentiated Thyroid Cancer
Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone
The goal of this study is to determine the effect of combining everolimus and sorafenib in patients with metastatic differentiated thyroid cancer who progressed on sorafenib alone.
- Trial name
- NCT01263951
- Testing
- Everolimus, Sorafenib
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Thomas Jefferson University
Neuroendocrine Tumors
Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study
Subjects achieving a clinical response in study OX4218s with a biomarker reduction or symptom response are eligible to enroll in this rollover study to continue once every three weeks fosbretabulin infusions for up to one year.
- Trial name
- NCT02279602
- Testing
- fosbretabulin
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- Mateon Therapeutics
Differentiated Thyroid Cancer, Thyroid Cancer
Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy
This study will be a multicentre prospective cohort study on TH-substitution after thyroid hormone withdrawal preceding radioiodine treatment.
- Conditions
- Differentiated Thyroid Cancer, Thyroid Cancer, Levothyroxine, Liothyronine
- Trial name
- THRIVE (NCT06647602)
- Testing
- Euthyrox (levothyroxine), Cytomel (liothyronine)
- Where
- 2 sites in Netherlands
- Volunteers
- 40 people
- Sponsor
- University Medical Center Groningen
Autism Spectrum Disorder (ASD
Exploring the Physiological Mechanisms of Austism Through Organoids
Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder affecting approximately 1% of the population, characterized by difficulties with social interaction and communication.
- Trial name
- EXPECT HYPE (NCT07494331)
- Where
- France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Sepsis, Septic Shock
Can Gdf-15 Level Predict Progression to Multiple Organ Failure in Patients With Septic Shock
The aim of this observational study is to investigate whether GDF-15 levels can predict clinical outcome in patients admitted to the intensive care unit with a diagnosis of septic shock.
- Conditions
- Sepsis, Septic Shock, Multi Organ Failure
- Trial name
- NCT06808100
- Where
- Turkey (Türkiye)
- Volunteers
- 250 people
- Sponsor
- Ankara City Hospital Bilkent
Regenerative Medicine, Induced Pluripotent Stem Cells (iPSC) Production
SAFE-iPS - France's First Hospital-based Platform for the Production of Induced Pluripotent Stem Cells for the Regenerative Medicine of the Future
The objective of the study is to establish the first French hospital-based Good Manufacturing Practice (GMP)-compliant platform for the production of clinical-grade induced pluripotent stem cells (iPSCs) for future regenerative…
- Trial name
- SAFE-iPS (NCT07735559)
- Testing
- Blood Collection for iPSC Generation
- Where
- France
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Basophilic Leukemia
Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes
This phase I trial is studying the side effects and best dose of tanespimycin when given with cytarabine in treating patients with relapsed or refractory acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7)
- Trial name
- NCT00098423
- Testing
- tanespimycin, cytarabine
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia
S0106A, Biomarkers in Samples From Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Cytarabine-Based Chemotherapy
RATIONALE: Studying samples of bone marrow and blood from patients with cancer in the laboratory may help doctors predict how well patients will respond to treatment.
- Trial name
- NCT01360125
- Testing
- proteomic profiling, flow cytometry, laboratory biomarker analysis
- Volunteers
- 310 people
- Sponsor
- SWOG Cancer Research Network
Neoplasms, Breast Neoplasms
Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer
A Phase 2, clinical study in advanced, metastatic breast cancer that will evaluate CX-2009 monotherapy in both Hormone Receptor(HR) positive/HER2 negative breast cancer and in TNBC, and evaluate CX-2009+CX-072 in TNBC
- Conditions
- Neoplasms, Breast Neoplasms, Breast Neoplasms, Triple-Negative, Breast Cancer
- Trial name
- NCT04596150
- Testing
- CX-2009, CX-072
- Where
- 42 sites in United States, South Korea and 1 more
- Volunteers
- 125 people
- Sponsor
- CytomX Therapeutics
Brain Tumor
Phenylbutyrate to Treat Children With Progressive or Recurrent Brain Tumors
This study will examine the safety and effectiveness of treating brain tumors in children with a continuous infusion of phenylbutyrate.
- Trial name
- NCT00006450
- Testing
- Phenylbutyrate
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Differentiated Thyroid Carcinoma, Papillary Thyroid Carcinoma
Bethesda Classification and Risk Stratification in Differentiated Thyroid Carcinoma
This observational study aims to evaluate the relationship between preoperative Bethesda classification of fine-needle aspiration cytology and postoperative American Thyroid Association (ATA) risk stratification in patients with…
- Conditions
- Differentiated Thyroid Carcinoma, Papillary Thyroid Carcinoma, Follicular Thyroid Carcinoma
- Trial name
- NCT07858097
- Volunteers
- 100 people
- Sponsor
- Assiut University
Gastroenteropancreatic Neuroendocrine Tumor
Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs
This is a multicentre long-term non-interventional study of adult subjects diagnosed with unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive GEP-NETs who have been prescribed…
- Trial name
- REAL-LU (NCT04727723)
- Testing
- Lutathera®
- Where
- 18 sites in Italy
- Volunteers
- 164 people
- Sponsor
- Novartis Pharmaceuticals
Pleural Thickening
Role of B Mode and Color Doppler Sonography in Differentiation Between Pleural Neoplasm and Inflammatory Pleural Thickening in Correlation With CT Findings
pleura is a serous membrane, it consist of parietal pleura and visceral pleura. pleural thickening is any form of thickening involving the pleura more than 3 mm.
- Trial name
- NCT05701462
- Testing
- biopsy under sonographic gidance
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Sohag University